Syntara pauses phase 1b trial for SNT-9465
Key points
- Syntara has paused recruitment in its Phase 1b trial of scar treatment SNT-9465 following reports of mild to moderate skin irritation.
- Company shares dropped 26.3% to trade at $0.014 on the ASX.
- The drugmaker will review unblinded patient data this quarter before deciding whether to resume or cancel the study.
Syntara (ASX:SNT) has halted enrolment in its Phase 1b clinical study evaluating topical pan-lysyl oxidase inhibitor SNT-9465 for hypertrophic scars after patient reports showed skin irritation.
The recruitment suspension follows an earlier trial expansion to 30 participants that had targeted top-line results in the first quarter of 2027.
"The feedback received from patients and trial sites during the study supported our decision to expand recruitment and open an additional clinical site to meet recruitment timelines," said Syntara CEO Gary Phillips.
Management stated that an unblinded data review of ongoing and completed patients will determine whether the trial resumes or terminates.
Following the announcement, the Syntara share price was down at $0.014.
The Phase 1b trial evaluated SNT-9465 on sternotomy scars to assess safety and local tolerability in adult patients.
The business is focused on advancing oral and topical lysyl oxidase inhibitors across clinical programmes targeting blood cancers and inflammatory scar tissue.
